A. Johnson

J. Byrd, K. Okkenhaug, J. Ritz, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.

J. Byrd, J. Ritz, D. Munn, 2014, The Journal of clinical investigation.

Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4

J. Byrd, J. Ritz, D. Munn, 2014 .

The Eµ-Myc/TCL1 Transgenic Mouse As a New Aggressive B-Cell Malignancy Model Suitable for Preclinical Therapeutics Testing

Lisa L. Smith, J. Byrd, A. Johnson, 2015 .

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.

Lisa L. Smith, J. Byrd, L. J. Lee, 2008, Blood.

The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study.

J. Byrd, I. Flinn, N. Heerema, 2012 .

The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study

J. Byrd, I. Flinn, N. Heerema, 2011 .

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, A. Johnson, 2011, Blood.

intracellular calcium leukemia cells with impaired oxygen consumption and mobilization of Flavopiridol causes early mitochondrial damage in chronic lymphocytic

M. Grever, J. Byrd, A. Johnson, 2013 .

Title: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes Short Title: Ibrutinib is an immunomodulatory ITK inhibitor

Lisa L. Smith, M. Caligiuri, J. Byrd, 2016 .

Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease

J. Byrd, C. Croce, L. Rassenti, 2013, PloS one.

Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeffrey A Jones, J. Byrd, I. Flinn, 2017, Clinical Cancer Research.

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2013, Leukemia research.

Glomerular beta-galactosidase expression following transduction with microsphere-adenoviral complexes.

N. Nahman, G. Nuovo, A. Johnson, 2002, Kidney international.

A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

Jeffrey A Jones, M. Grever, J. Byrd, 2016, Annals of Hematology.

Brief report The role of phosphatidylinositol 3-kinase- (cid:1) in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia

J. Byrd, A. Johnson, K. Blum, 2011 .

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Jeffrey A Jones, J. Byrd, F. Awan, 2016, The New England journal of medicine.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Juthamas Sukbuntherng, Susan O'Brien, Jeffrey A Jones, 2013, The New England journal of medicine.

Phosphatidylinositol 3-kinase- inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Jeffrey A Jones, J. Byrd, N. Heerema, 2010 .

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.

Derek A. West, M. Grever, J. Byrd, 2009, Blood.

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

J. Byrd, K. Coombes, A. Johnson, 2016, PloS one.

Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.

Jeffrey A Jones, J. Byrd, A. Johnson, 2013, Blood.

response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014 .

The B-cell receptor signaling pathway as a therapeutic target in CLL.

J. Byrd, A. Johnson, John C Byrd, 2012, Blood.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Lisa L. Smith, J. Byrd, A. Johnson, 2014, Blood.

Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.

A. Johnson, S. E. Herman, 2012, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genetic heterogeneity of diffuse large B-cell lymphoma

David Dunson, Ting Ni, Anjishnu Banerjee, 2013, Proceedings of the National Academy of Sciences.

Isolation and analysis of linker histones across cellular compartments.

Michael A. Freitas, J. Byrd, A. Johnson, 2013, Journal of proteomics.

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Jeffrey A Jones, J. Byrd, A. Johnson, 2015, Blood.

Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity

M. Caligiuri, M. Grever, J. Byrd, 2007, Clinical Cancer Research.

Mitochondrial Priming of Chronic Lymphocytic Leukemia Patients Associates Bcl-xL Dependence with Alvocidib Response

M. Grever, J. Byrd, W. Pierceall, 2014, Leukemia.

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

J. Byrd, S. Dave, P. Lichter, 2014, The New England journal of medicine.

Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

J. Byrd, J. Gribben, A. Johnson, 2008, The Journal of clinical investigation.

Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets

Lisa L. Smith, J. Byrd, C. Plass, 2004, Cancer Research.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2015, JAMA oncology.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

J. Byrd, A. Johnson, J. Flynn, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.

J. Byrd, A. Johnson, C. Crews, 2018, Biochemistry.

A Novel Celecoxib Derivative , OSU 03012 , Induces Cytotoxicity in Primary CLL Cells and Transformed B-cell Lymphoma via a Caspase and Bcl-2 Independent Mechanism

Lisa L. Smith, J. Byrd, N. Heerema, 2004 .

Optimizing extracellular vesicles’ isolation from chronic lymphocytic leukemia patient plasma and cell line supernatant

A. Johnson, E. Cocucci, X. Mo, 2021, JCI insight.

Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells.

Xueqin Song, S. Kulp, Ping-Hui Tseng, 2002, Journal of the National Cancer Institute.

OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms

A. Johnson, S. Farag, A. Suvannasankha, 2007, Clinical Cancer Research.

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Jeffrey A Jones, J. Byrd, N. Heerema, 2015, Blood.

Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL.

Derek A. West, J. Byrd, J. Qian, 2011, Blood.

Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia

J. Byrd, C. Plass, Y. Pekarsky, 2009, Proceedings of the National Academy of Sciences.

PI3K p110&dgr; inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression

J. Byrd, A. Johnson, Jennifer R. Brown, 2018, The Journal of clinical investigation.

Cl inic in Chronic Lymphocyt ic Leukemia : The Story of CAL-101 ( GS 1101 ) By

J. Byrd, A. Johnson, J. Woyach, 2012 .

The phosphatidylinositol 3-kinase-δ Inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Jeffrey A Jones, Weiqiang, J. Byrd, 2010 .

independent mechanism - Bcl-2 CLL cells and transformed B-cell lymphoma cell line via a caspase- and A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary

Lisa L. Smith, M. Grever, J. Byrd, 2013 .

in chronic lymphocytic leukemia Selective inhibitors of nuclear export show that CRM1/XPO1 is a target

J. Byrd, A. Johnson, D. Lucas, 2013 .

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Yuh Min Chook, David Lucas, J. Byrd, 2012, Blood.

A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism.

Lisa L. Smith, M. Grever, J. Byrd, 2004, Blood.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2013, Blood.

Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia

Jeffery A. Jones, J. Byrd, C. Plass, 2016, Oncotarget.

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

J. Byrd, A. Johnson, Lianbo Yu, 2015, Blood.

17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition.

Derek A. West, Jeffrey A Jones, J. Byrd, 2008, Blood.

Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition

M. Grever, J. Byrd, W. Sadee, 2010, PloS one.

Plenary paper Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

M. Grever, J. Byrd, B. Rovin, 2006 .

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009, Leukemia & lymphoma.

Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2009 .

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Jeffrey A Jones, J. Byrd, A. Johnson, 2011, Blood.

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, A. Johnson, 2015, Blood.

Key points

Jeffrey A Jones, J. Byrd, A. Johnson, 2019, Copyright for Archivists and Records Managers.

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

David A. Williams, J. Byrd, A. Johnson, 2012, Blood.

Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center

Jeffrey A Jones, M. Grever, J. Byrd, 2014, Leukemia.

Targeted therapies in CLL: mechanisms of resistance and strategies for management.

A. Johnson, J. Woyach, 2015, Blood.

Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia (cll).

Emily M. Thrash, S. Tyekucheva, A. Johnson, 2021, Blood.

VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia

J. Byrd, A. Johnson, J. Blachly, 2022, Leukemia.

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Lisa L. Smith, J. Byrd, A. Johnson, 2010, Blood.

Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.

M. Grever, J. Byrd, T. Kipps, 2015, Leukemia research.

Advances in the therapy of chronic lymphocytic leukemia.

J. Byrd, A. Johnson, A. Mone, 2003, Current opinion in hematology.

Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia

Jeffrey A Jones, J. Byrd, I. Flinn, 2016 .

Modulation of immune checkpoint molecule expression in mantle cell lymphoma

Lisa L. Smith, J. Byrd, A. Johnson, 2019, Leukemia & lymphoma.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Lisa L. Smith, R. Ulrich, J. Byrd, 2016, Clinical Cancer Research.

Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma

J. Byrd, A. Johnson, W. Kisseberth, 2014 .

BTK C 481 S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

M. Grever, J. Byrd, F. Awan, 2017 .

Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL).

J. Byrd, A. Johnson, S. Stilgenbauer, 2013 .

Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemiain vitroand inhibits C481S mutated Bruton tyrosine kinase

J. Byrd, A. Johnson, J. Fox, 2017 .

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

Preliminary Results of a Phase I Study of Lenalidomide in Relapsed Chronic Lymphocytic Leukemia.

J. Byrd, A. Johnson, K. Blum, 2009 .

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

Guido Marcucci, Amy J. Johnson, John C. Byrd, 2014, Leukemia.

Translating PI3K-Delta Inhibitors to the Clinic in Chronic Lymphocytic Leukemia: The Story of CAL-101 (GS1101).

J. Byrd, A. Johnson, J. Woyach, 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Update on the Phase I Study of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH 727965) In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity and Feasibility of Long-Term Administration

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Jeffrey A Jones, M. Caligiuri, J. Byrd, 2016 .

Identification of endoplasmic reticulum stress-inducing agents by antagonizing autophagy: a new potential strategy for identification of anti-cancer therapeutics in B-cell malignancies

Jeffrey A Jones, J. Byrd, A. Johnson, 2013, Leukemia & lymphoma.

Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach

Jeffrey A Jones, M. Grever, J. Byrd, 2012, Haematologica.

Risk Factors for Tumor Lysis Syndrome in patients with Chronic Lymphocytic Leukemia Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol

Jeffrey A Jones, M. Grever, J. Byrd, 2011, Leukemia.

Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities

Jeffrey A Jones, M. Grever, J. Byrd, 2008 .

Activating MAPK Pathway Mutations Mediate Primary Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia (CLL)

S. Tyekucheva, A. Johnson, S. Kasar, 2018, Blood.

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2016 .

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features

Jeffrey A Jones, J. Byrd, N. Heerema, 2016 .

A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.

Jeffrey A Jones, M. Grever, J. Byrd, 2012 .

Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients.

Jeffrey A Jones, M. Grever, J. Byrd, 2014 .

OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.

Jeffrey A Jones, J. Byrd, F. Awan, 2015, Blood.

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

A. Johnson, R. Baiocchi, B. Christian, 2019, Blood.

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo

Derek A. West, Michael A. Freitas, M. Grever, 2010, PloS one.

Might broader be better?

A. Johnson, 2017, Blood.

Ibrutinib (PCI-32765) Antagonizes Rituximab-Dependent NK-Cell Mediated Cytotoxicity

J. Byrd, A. Johnson, N. Muthusamy, 2013 .

A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: the Combination of Idelalisib and Rituximab

A. Johnson, Ta-Ming Liu, Postdoc Journal, 2014 .

Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma.

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2009 .

Interim Results of a Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia

J. Byrd, R. Garzon, A. Johnson, 2016 .

Cells, cytokines, chemokines, and cancer stress: A biobehavioral study of patients with chronic lymphocytic leukemia

J. Byrd, A. Johnson, B. Andersen, 2018, Cancer.

Biodegradable Microparticles for in vivo Glomerular Targeting: Implications for Gene Therapy of Glomerular Disease

N. Nahman, L. Brannon-Peppas, A. Johnson, 2002 .

Cancer-Specific Stress and Trajectories of Psychological and Physical Functioning in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.

J. Byrd, A. Johnson, B. Andersen, 2018, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

Pharmacokinetics and Tissue Disposition of Lenalidomide in Mice

J. Byrd, A. Johnson, Xiaobai Li, 2012, The AAPS Journal.

Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2007 .

A Dose Escalation Study of Ibrutinib with Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

J. Byrd, A. Johnson, M. Phelps, 2014 .

Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

I. Flinn, A. Johnson, K. Rogers, 2022, Blood.

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2012, Leukemia.

Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2013 .

Mighty mouse.

A. Johnson, 2009, Blood.

A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Jeffrey A Jones, J. Byrd, A. Johnson, 2016, Leukemia & lymphoma.

ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity

R. Ulrich, J. Byrd, A. Johnson, 2015 .

Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells

Jeffrey A Jones, Lisa L. Smith, M. Caligiuri, 2012 .

Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients

J. Byrd, A. Johnson, N. Muthusamy, 2015 .

Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling.

J. Byrd, A. Johnson, Lianbo Yu, 2015, Blood.

Risk Factors for Tumor Lysis Syndrome (TLS) In Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Cyclin Dependent Kinase Inhibitor, Flavopiridol.

Jeffrey A Jones, M. Grever, J. Byrd, 2010 .

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, I. Flinn, 2013, The New England journal of medicine.

LYMPHOID NEOPLASIA Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Jeffrey A Jones, M. Caligiuri, A. Johnson, 2013 .

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.

Jeffrey A Jones, J. Byrd, N. Heerema, 2014, The Lancet. Oncology.

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

David A. Williams, J. Byrd, A. Johnson, 2012, Blood.

Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia

M. Grever, J. Byrd, N. Heerema, 2014, Oncotarget.

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, F. Awan, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL)

Jeffrey A Jones, M. Grever, J. Byrd, 2015, American journal of hematology.

The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.

Derek A. West, N. Heerema, A. Johnson, 2009, Blood.

Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol

J. Byrd, A. Johnson, Emilia Mahoney, 2013, Autophagy.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Variability of polymerase chain reaction detection of the bcl-2-IgH translocation in an international multicentre study.

G. Salles, D. Colomer, R. Gupta, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Andrew W. Greaves, D. Neuberg, L. Rassenti, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Jeffrey A Jones, J. Byrd, A. Johnson, 2011, Blood.

Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

Isolation and analysis of linker histones across cellular compartments.

Michael A. Freitas, J. Byrd, A. Johnson, 2013, Journal of proteomics.

A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol

M. Grever, J. Byrd, D. Mould, 2013, Clinical Cancer Research.

Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2013, Leukemia research.

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment

A. Johnson, G. Lozanski, H. Tu, 2017, Leukemia.

Ibrutinib treatment ameliorates murine chronic graft-versus-host disease

D. Munn, J. Serody, A. Johnson, 2014 .